THF-.gamma.2 analogs and pharmaceutical compositions comprising them
AssigneeYeda Research and Developement Co. Ltd.
InventorsYigal Burstein, Nathan Trainin
Life of this patent
Estimating the term…
Abstract
An immunomodulatory peptide is disclosed which is a thymic humoral factor .gamma.2 (THF-.gamma.2) analog of at least eight amino acids or a functional derivative or a salt thereof. The peptide has the amino acid sequence: Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu (SEQ ID No:1) but differing therefrom by (i) addition of one to three amino acids at the N- and/or C-terminus; (ii) substitution of one to four amino acids by a protein natural or non-natural amino acid; (iii) cyclization through a free carboxyl group and a free amino group or through disulfide bonds of cysteines residues; or (iv) linkage of two to four sequences of modified sequences of (I) corresponding to anyone of (i), (ii), or (iii) above, through a peptidic or non-peptidic linkage.
Claims10
A peptide being a thymic humoral factor .gamma.2 (THF-.gamma.2) analog of at least eight amino acids or a functional derivative or a salt thereof, able to enhance by at least 30% either concanavalin A (ConA)-induced IL-2 production in mouse spleen cells and/or the number of granulocyte-monocyte colony forming cells of mouse bone marrow, said peptide having the sequence of THF-.gamma.2 of the formula I (SEQ ID No:1):
- Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu (I) 1 2 3 4 5 6 amino acid number
- but differing therefrom by
- (i) addition of one to three amino acids at the N- and/or C-terminus;
- or
- (ii) linkage of two to four sequences of sequence I or a modified sequence of (I) corresponding to (i) above, through a peptidic or non-peptidic linkage.
Dependencies are inferred from the claim text.